Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls

by Marc Pawlitzki, Julia Uebelhör, Catherine M. Sweeney-Reed, Heike Stephanik, Juliane Hoffmann, Anke Lux, Dirk Reinhold
Published 2018-07-01

Come avviare la terapia nel paziente naïve: Scelta dei farmaci sulle caratteristiche della malattia e del paziente

by Massimiliano Mirabella
Published 2015-12-01

Фенотипические особенности и клиническая неоднородность антисинтетазного синдрома

by Olga Alekseyevna Antelava, E L Nasonov
Published 2013-10-01

Basic Mechanisms of JAK Inhibition

by Chung MA Lin, Faye AH Cooles, John D. Isaacs
Published 2020-01-01

Nuovi schemi terapeutici nella sclerosi multipla

by Maria Pia Amato
Published 2015-12-01

Comorbidity in US patients with multiple sclerosis

by Edwards NC, Munsell M, Menzin J, Phillips AL
Published 2018-02-01

Sulfasalazine efficacy and tolerability in rheumatic diseases

by V. V. Badokin
Published 2005-08-01

Come modificare la terapia nel paziente experienced

by Maria Giovanna Marrosu
Published 2015-12-01

DOES THE TYPE OF DISEASE-MODIFYING DRUGS IMPACT ON THE QUALITY OF LIFE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS?

by Amirreza NASERI, Ehsan NASIRI, Malihe TALEBI, Kimia KARIMI, Mahnaz TALEBI
Published 2020-09-01

Family Planning Decision Making in People With Multiple Sclerosis

by Simona Bonavita, Simona Bonavita, Luigi Lavorgna, Hilary Worton, Susan Russell, Susan Russell, Dominic Jack
Published 2021-04-01

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region

by Raed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, Jaber Alkhabouri, Taoufik Alsaadi, Abdullah Alsalti, Amir Boshra, Beatriz Canibano, Samar Farouk Ahmed, Ahmed Shatila
Published 2020-06-01

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

by Serena Brancati, Lucia Gozzo, Lucia Gozzo, Laura Longo, Daniela Cristina Vitale, Filippo Drago, Filippo Drago, Filippo Drago
Published 2021-07-01

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

by Oo WM, Little C, Duong V, Hunter DJ
Published 2021-07-01

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion

by Raed Alroughani, Jihad Said Inshasi, Dirk Deleu, Jasem Al-Hashel, Mustafa Shakra, Osama Robin Elalamy, Ahmed Osman Shatila, Abdullah Al-Asmi, Isa Al Sharoqi, Beatriz Garcia Canibano, Amir Boshra
Published 2019-03-01

Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production

by Maria Blonda, Antonella Amoruso, Roberta Grasso, Valeria Di Francescantonio, Carlo Avolio
Published 2017-08-01

Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey

by Christian P. Kamm, Christian P. Kamm, Sarah Muehl, Dennis Mircsof, Stefanie Müller, Adam Czaplinski, Lutz Achtnichts, Petra Stellmes, Gabrielle Di Virgilio
Published 2018-10-01

Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis – impact of treatment

by Piotr Dąbrowski, Maria Majdan
Published 2014-06-01

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes

by Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph A. DeFronzo, Itamar Raz
Published 2021-04-01

From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside

by Elena Rezuş, Alexandra Burlui, Anca Cardoneanu, Luana Andreea Macovei, Bogdan Ionel Tamba, Ciprian Rezuş
Published 2021-03-01

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

by N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika
Published 2020-10-01